DNER and acute myeloid leukemia: BET inhibitors have demonstrated remarkable efficacy in preclinical models and promising results in clinical trials of hematologic malignancies including acute myeloid leukemia (AML), acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin’s lymphoma15,18,19.